77 related articles for article (PubMed ID: 5118685)
1. Preliminary clinical trials and clinical pharmacologic studies with 5-(3,3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196) given orally.
Vogel CL; DeVita VT; Denham C; Foley HT; Field RB; Carbone PP
Cancer Chemother Rep; 1971 Apr; 55(2):159-65. PubMed ID: 5118685
[No Abstract] [Full Text] [Related]
2. 5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
van Eden EB; Falkson G; van Dyk JJ; van der Merwe AM; Falkson HC
Cancer Chemother Rep; 1972 Feb; 56(1):107-47. PubMed ID: 5030803
[No Abstract] [Full Text] [Related]
3. Metabolism of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5(4)-carboxamide to 4(5)-aminoimidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Biochem Pharmacol; 1970 Jun; 19(6):2043-51. PubMed ID: 5513972
[No Abstract] [Full Text] [Related]
4. Influence of treatment schedules and route of administration on the chemotherapy of murine leukemia L1210 with 5(or 4)-[3,3-bis( 2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196).
Hoffman G; Kline I; Gang M; Tyrer DD; Venditti JM; Goldin A
Cancer Chemother Rep; 1968 Dec; 52(7):715-24. PubMed ID: 5743709
[No Abstract] [Full Text] [Related]
5. Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man.
Skibba JL; Ramirez G; Beal DD; Bryan GT
Cancer Res; 1969 Nov; 29(11):1944-51. PubMed ID: 5358212
[No Abstract] [Full Text] [Related]
6. 5-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy.
Komp DM; Land VJ; Nitschke R; Cangir A; Dyment P
Cancer Chemother Rep; 1975; 59(2 Pt 1):371-6. PubMed ID: 1097094
[No Abstract] [Full Text] [Related]
7. Combination chemotherapy with CCNU (NSC-79037) and 5-(3, 3-bis(2-chloroethyl)-1-triazeno)-imidazole-4-carboxamide (NSC-82196).
Chang H; Freireich EJ; Khaliq A; Einhorn L; Gottlieb JA
Cancer Chemother Rep; 1975; 59(4):769-71. PubMed ID: 1100230
[No Abstract] [Full Text] [Related]
8. Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196).
Kline I; Woodman RJ; Gang M; Venditti JM
Cancer Chemother Rep; 1971 Feb; 55(1):9-28. PubMed ID: 5121657
[No Abstract] [Full Text] [Related]
9. Phase II study of 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in advanced gastrointestinal cancer.
Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
Cancer Chemother Rep; 1972 Apr; 56(2):267-9. PubMed ID: 5043230
[No Abstract] [Full Text] [Related]
10. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel CL; Denham C; Waalkes TP; DeVita VT
Cancer Res; 1970 Jun; 30(6):1651-7. PubMed ID: 5457935
[No Abstract] [Full Text] [Related]
11. Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
Cowan DH; Bergsagel DE
Cancer Chemother Rep; 1971 Apr; 55(2):175-81. PubMed ID: 5118686
[No Abstract] [Full Text] [Related]
12. Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors.
Levin VA; Crafts D; Wilson CB; Kabra P; Hansch C; Boldrey E; Enot J; Neely M
Cancer Chemother Rep; 1975; 59(2 Pt 1):327-31. PubMed ID: 1149010
[No Abstract] [Full Text] [Related]
13. Adaptation of a colorimetric determination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (NSC-45388) and 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) to blood.
Field RB; Hoffman G; Waravdekar VS; Kline I
Cancer Chemother Rep; 1969 Jun; 53(3):199-202. PubMed ID: 4980814
[No Abstract] [Full Text] [Related]
14. Pharmacologic studies of the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide.
Loo TL; Luce JK; Jardine JH; Frei E
Cancer Res; 1968 Dec; 28(12):2448-53. PubMed ID: 5728154
[No Abstract] [Full Text] [Related]
15. Kinetics of the effect of 5(or 4)-(3,3-dimethyl-1-triazeno)-imidazole-4 (or 5) -carboxamide (NSC-45388) and 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196) on the reproductive integrity of cultured leukemia L1210 cells.
Wilkoff LJ; Dulmadge EA; Dixon GJ
Cancer Chemother Rep; 1968 Dec; 52(7):725-32. PubMed ID: 5754670
[No Abstract] [Full Text] [Related]
16. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
[No Abstract] [Full Text] [Related]
17. Clinical trials of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) given intravenously in the treatment of malignant melanoma in Uganda.
Vogel CL; Comis R; Ziegler JL; Kiryabwire JW
Cancer Chemother Rep; 1971 Apr; 55(2):143-9. PubMed ID: 5118684
[No Abstract] [Full Text] [Related]
18. Study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with disseminated melanoma.
Gerner RE; Moore GE
Cancer Chemother Rep; 1973 Feb; 57(1):83-4. PubMed ID: 4704107
[No Abstract] [Full Text] [Related]
19. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley CM; Canellos GP; Young RC; Gallelli JF; Devita VT
Cancer Chemother Rep; 1972 Jun; 56(3):387-91. PubMed ID: 19051499
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.
Falkson G; Van der Merwe AM; Falkson HC
Cancer Chemother Rep; 1972 Oct; 56(5):671-7. PubMed ID: 4569061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
